Clinical and radiologic outcomes in two patients with multiple sclerosis treated with tocilizumab for COVID-19

ABSTRACT:

Background

Tocilizumab is an interleukin-6 receptor antagonist used to treat COVID-19. A previous case report described development of multiple sclerosis (MS) after treatment with tocilizumab for rheumatoid arthritis, leading to an FDA warning label. We sought to identify patients with multiple sclerosis (MS) who were treated with tocilizumab for coronavirus disease 2019 (COVID-19) and characterize clinical outcomes.

Methods

We electronically identified MS patients who received tocilizumab for COVID-19 from January 2019 to September 2021 and performed retrospective chart review.

Results

Two patients were identified. The patients were both treated with ocrelizumab and had an average disease duration of 10.5 years. Both patients were hospitalized with COVID-19 infe

SUBMITTER:  

PROVIDER: S-EPMC8750953 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature